Related Experiment Video
Updated: Apr 24, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.6K
Warfarin pharmacogenomics: recommendations with available patented clinical technologies
Andrew A Borkowski, Avni Kardani, Stephen M Mastorides
1P&LMS (113), 13000 Bruce B. Downs Blvd, Tampa, FL 33612, USA. Andrew.borkowski@va.gov.
Recent Patents on Biotechnology
|September 5, 2014
Summary
Warfarin dosing variability is significantly influenced by genetic factors. Pharmacogenomic testing for CYP2C9 and VKORC1 gene variants improves warfarin therapy personalization and clinical outcomes.
Area of Science:
- Clinical Pharmacology
- Genetics
- Laboratory Medicine
Background:
- Warfarin is a widely prescribed anticoagulant with significant interindividual dose variability.
- Genetic polymorphisms in key enzymes contribute substantially to variable warfarin dose requirements.
- Personalized medicine approaches are crucial for optimizing warfarin therapy.
Purpose of the Study:
- To review the clinical utility of pharmacogenomic testing for warfarin dosing.
- To discuss the impact of CYP2C9 and VKORC1 gene variants on warfarin response.
- To propose a model for implementing pharmacogenomic test results in clinical practice.
Main Methods:
- Review of scientific literature on warfarin pharmacogenomics.
- Analysis of genetic polymorphisms in CYP2C9 and VKORC1.
- Discussion of clinical implementation strategies and commercial testing platforms.
Main Results:
- Genetic variations in CYP2C9 and VKORC1 explain 35-50% of warfarin dose variability.
- Pharmacogenomic testing can guide more precise warfarin dosing.
- Commercial testing platforms are available, but present implementation complexities.
Conclusions:
- Pharmacogenomic testing is a valuable tool for personalized warfarin therapy.
- Implementation of genetic testing requires careful consideration of clinical models and platform complexities.
- Optimizing warfarin dosing through genetic insights enhances patient safety and treatment efficacy.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
188
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
188
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:29Pharmacogenomics: Identification of New Drug Targets
117
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
117
01:29Pharmacogenetics and Pharmacogenomics: Overview
238
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
238
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K